文献速递神经肿瘤

剂量递增代谢治疗联合同步放疗治疗高级别胶质瘤的I期临床试验

A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
PubMed 文献 · J Neurooncol · 2021-06-21

单中心I期试验纳入13例高级别胶质瘤患者,评估改良阿特金斯饮食联合中链甘油三酯及二甲双胍联合同步放疗的耐受性与可行性。干预总体耐受良好,无严重不良事件;二甲双胍850mg每日三次耐受性差。血酮水平与生酮比、二甲双胍使用及低胰岛素水平相关。推荐II期剂量为8周ModAD联合二甲双胍850mg每日两次。

要点

  • 代谢干预联合同步放疗耐受良好,无严重不良事件。
  • 二甲双胍850mg每日三次耐受性差,推荐II期剂量为每日两次。
  • 血酮水平与生酮比、二甲双胍使用及低胰岛素水平相关。

核心结论

  • 该代谢干预联合同步放疗方案耐受良好,推荐II期剂量为8周ModAD联合二甲双胍850mg每日两次。

研究设计与样本

  • 单中心I期临床试验,共纳入13例高级别胶质瘤患者,中位年龄61岁,其中新诊断6例、复发7例。
  • 放疗剂量为新诊断60Gy/6周、复发35Gy/2周;饮食干预为改良阿特金斯饮食补充中链甘油三酯。
  • 设三个队列:单纯饮食干预、饮食干预联合低剂量二甲双胍、饮食干预联合高剂量二甲双胍,所有患者均接受放疗。

主要发现

  • 全部患者完成放疗,5例提前停止代谢干预;二甲双胍850mg每日三次耐受性差,无严重不良事件。

关键数值与推荐

  • 推荐II期剂量为8周改良阿特金斯饮食联合二甲双胍850mg每日两次。

临床怎么用

  • 高级别胶质瘤同步放疗期间可考虑代谢干预,但二甲双胍850mg每日三次耐受性差,应选用每日两次方案。
  • 监测血酮、胰岛素水平及饮食生酮比有助于评估代谢干预依从性与效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Animal brain-tumor models have demonstrated a synergistic interaction between radiation therapy and a ketogenic diet (KD). Metformin has in-vitro anti-cancer activity, through AMPK activation and mTOR inhibition. We hypothesized that the metabolic stress induced by a KD combined with metformin would enhance radiation's efficacy. We sought to assess the tolerability and feasibility of this approach. METHODS: A single-institution phase I clinical trial. Radiotherapy was either 60 or 35 Gy over 6 or 2 weeks, for newly diagnosed and recurrent gliomas, respectively. The dietary intervention consisted of a Modified Atkins Diet (ModAD) supplemented with medium chain triglycerides (MCT). There were three cohorts: Dietary intervention alone, and dietary intervention combined with low-dose or high-dose metformin; all patients received radiotherapy. Factors associated with blood ketone levels were investigated using a mixed-model analysis. RESULTS: A total of 13 patients were accrued, median age 61 years, of whom six had newly diagnosed and seven with recurrent disease. All completed radiation therapy; five patients stopped the metabolic intervention early. Metformin 850 mg three-times daily was poorly tolerated. There were no serious adverse events. Ketone levels were associated with dietary factors (ketogenic ratio, p < 0.001), use of metformin (p = 0. 02) and low insulin levels (p = 0.002). Median progression free survival was ten and four months for newly diagnosed and recurrent disease, respectively. CONCLUSIONS: The intervention was well tolerated. Higher serum ketone levels were associated with both dietary intake and metformin use. The recommended phase II dose is eight weeks of a ModAD combined with 850 mg metformin twice daily.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Porper K, Shpatz Y, Plotkin L, et al. A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma. J Neurooncol. 2021. PMID: 34152528. doi:10.1007/s11060-021-03786-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。